Wantai Biopharmaceutical: Recombinant Respiratory Syncytial Virus Vaccine Obtains Clinical Trial Approval Notice

2026-03-16 08:50:18

People’s Financial News, March 16 — Wantai Biotech (603392) announced on March 16 that by December 2025, its wholly-owned subsidiary Wantai Canghai received the administrative permit acceptance notice from the National Medical Products Administration. The company’s application for clinical trials of the “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)” has been accepted. Recently, Wantai Canghai received the approval notice for clinical trials of the recombinant respiratory syncytial virus vaccine (CHO cells) issued by the National Medical Products Administration.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.